Global Alzheimer's Platform Foundation and Genentech Partner to Enhance Diversity in Alzheimer's Clinical Trials
核心洞察
The Global Alzheimer's Platform Foundation (搜索) and Genentech announced a collaboration to expand access to Alzheimer's clinical trials for underrepresented communities, including racial and ethnic minorities, women, and economically disadvantaged individuals.
The partnership will leverage GAP's Site Alliance for Understudied Communities and Genentech's Advancing Inclusive Research Site Alliance to remove barriers to clinical research participation.
Genentech will activate specialized clinical trial sites from GAP's network for several Alzheimer's disease studies, focusing on community-based education and inclusive recruitment practices.
The Global Alzheimer's Platform Foundation (搜索) (GAP) and Genentech, a member of the Roche Group, have announced a strategic collaboration to expand access to clinical trials for communities underrepresented in Alzheimer's research. The partnership aims to address the critical need for greater diversity in Alzheimer's disease studies by combining the expertise of both organizations' specialized site networks.
Addressing Representation Gaps in Alzheimer's Research
The collaboration will leverage GAP's Site Alliance for Understudied Communities (SAUC) and Genentech's Advancing Inclusive Research (AIR) Site Alliance to remove barriers to clinical research participation. The initiative specifically targets enhancing representation from understudied groups in Alzheimer's research, including racial and ethnic minorities, women, and individuals who are economically and educationally disadvantaged.
"To truly understand and treat Alzheimer's disease, we must include the voices and experiences of all communities. Inclusive research leads to better science, more accurate findings, and treatments that serve everyone—not just those historically represented," said Tamiko Magee-Rodgers, PhD, assistant vice president, Trial Execution Services, GAP.
Strategic Implementation and Site Activation
As part of the collaboration, Genentech will activate clinical trial sites from GAP's SAUC for several of their Alzheimer's disease studies. These specialized sites will focus on increasing the enrollment of understudied populations by prioritizing community-based education and implementing inclusive recruitment practices.
The partnership will provide study education and resources to encourage access to studies, while equipping sites with the necessary educational tools, training and outreach support to understand and overcome barriers to improving representation in Alzheimer's disease research.
Commitment to Scientific Progress and Community Trust
John Dwyer, President of the Global Alzheimer's Platform Foundation (搜索), emphasized the scientific imperative for inclusive research. "At GAP, we believe that Alzheimer's research must recruit participants reflecting the incidence of the disease; this is essential to scientific progress. By including people from communities across all demographics, we not only improve the quality of our data—we build trust in science, accelerate innovation, and move closer to treatments that work for everyone," he stated.
Dwyer added that the organization is proud to work alongside Genentech, noting their shared commitment to advancing best practices in clinical trials. "By prioritizing access for understudied populations, we aim to ensure that breakthrough technologies benefit all communities affected by Alzheimer's disease."
Expanding Access Through Alliance Networks
Meghan McKenzie, portfolio alliance lead, Population Science at Genentech, highlighted the significance of expanding the AIR Site Alliance into Alzheimer's disease research. "By expanding the AIR Site Alliance into Alzheimer's Disease in collaboration with GAP, we have the opportunity to directly address the critical need for greater representation and access to Alzheimer's research for all patients," McKenzie said. "This work reflects our ongoing commitment to optimizing health outcomes for all and ensuring that all eligible patients can benefit from transformative scientific innovation."
Foundation's Broader Mission
The nonprofit Global Alzheimer's Platform Foundation (搜索) was founded to speed the delivery of Alzheimer's treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible.